KPTI Karyopharm Therapeutics Inc.

4.72
+0.09  (+2%)
Previous Close 4.63
Open 4.65
Price To Book 1.57
Market Cap 287280180
Shares 60,864,445
Volume 154,423
Short Ratio
Av. Daily Volume 1,992,289

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 3 top-line data due in 2020.
Selinexor - SEAL
Dedifferentiated liposarcoma
PDUFA date under priority review extended by three months to July 6, 2019. Advisory Committee February 26, 2019 voted 8-5 recommending that approval decision is held off until after the release of data from BOSTON trial, late-2019/2020.
Selinexor
Quadruple Refractory Multiple Myeloma
Phase 3 data due end of 2019 or into 2020.
Selinexor - BOSTON
Multiple myeloma
NDA filing due 2019.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)
Phase 3 top-line data due 2020.
Selinexor - SIENDO
Endometrial cancer
Phase 2 data due 1H 2019.
Eltanexor
Solid tumors
Phase 1/2 updated tolerability data due 2Q 2019.
KPT-9274
Non-Hodgkin Lymphoma

Latest News

  1. Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Are Analysts Bullish?
  2. Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  3. Here's Why Karyopharm Therapeutics Climbed Today
  4. Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
  5. Why Karyopharm Therapeutics Stock Is Soaring Today
  6. The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA
  7. Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
  8. Edited Transcript of KPTI earnings conference call or presentation 28-Feb-19 1:30pm GMT
  9. Take a Poker Player's Approach to Playing Small Biotech Stocks
  10. Steven Cohen Ups Bet on Karyopharm Therapeutics
  11. Karyopharm Therapeutics Inc (KPTI) Q4 2018 Earnings Conference Call Transcript
  12. Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  13. Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback
  14. The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings
  15. Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
  16. Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
  17. The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote
  18. Karyopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer
  19. FDA panel says Karyopharm's cancer drug shows 'significant toxicity'